Archivio istituzionale della ricerca dell'Università degli Studi di Palermo
IRIS è il sistema di gestione integrata dei dati della ricerca (persone, pubblicazioni, progetti, attività) adottato dall’Università di Palermo, e ha lo scopo di raccogliere, conservare, documentare, e diffondere ad accesso aperto le informazioni relative alla produzione scientifica degli autori afferenti all’Ateneo.
EnglishDespite the existence of multimodal therapy paradigm, high-grade gliomas (HGGs) remain devastating tumors associated with one of the worst prognoses. Glioblastoma (GBM) is the most frequent reported histologic type with a median survival, after surgery and combined treatment with chemotherapy and radiotherapy, ranging from 12 to 16 months. The poor prognosis is due to the lack of therapeutic efficacy of chemical agents and irradiation in hypoxic tumor areas. Experimental studies have investigated several molecules with the aim to counteract several downstream signaling important in tumor progression, unfortunately without conclusive results. Several studies have shown that the extent of resection improves survival in patients with HGG, although the quest to achieve optimal oncologic outcomes must be tempered with the neurologic result after radical resection.
Grasso, G., & Torregrossa, F. (2020). Magnetic Resonance Spectrobiopsy for Prediction of Isocitrate Dehydrogenase Mutation in Glioma. WORLD NEUROSURGERY, 134, 187-189 [10.1016/j.wneu.2019.10.181].
| Data di pubblicazione: | 2020 | |
| Titolo: | Magnetic Resonance Spectrobiopsy for Prediction of Isocitrate Dehydrogenase Mutation in Glioma | |
| Autori: | ||
| Citazione: | Grasso, G., & Torregrossa, F. (2020). Magnetic Resonance Spectrobiopsy for Prediction of Isocitrate Dehydrogenase Mutation in Glioma. WORLD NEUROSURGERY, 134, 187-189 [10.1016/j.wneu.2019.10.181]. | |
| Rivista: | ||
| Digital Object Identifier (DOI): | http://dx.doi.org/10.1016/j.wneu.2019.10.181 | |
| Abstract: | Despite the existence of multimodal therapy paradigm, high-grade gliomas (HGGs) remain devastating tumors associated with one of the worst prognoses. Glioblastoma (GBM) is the most frequent reported histologic type with a median survival, after surgery and combined treatment with chemotherapy and radiotherapy, ranging from 12 to 16 months. The poor prognosis is due to the lack of therapeutic efficacy of chemical agents and irradiation in hypoxic tumor areas. Experimental studies have investigated several molecules with the aim to counteract several downstream signaling important in tumor progression, unfortunately without conclusive results. Several studies have shown that the extent of resection improves survival in patients with HGG, although the quest to achieve optimal oncologic outcomes must be tempered with the neurologic result after radical resection. | |
| URL: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85075553273&doi=10.1016/j.wneu.2019.10.181&partnerID=40&md5=5a2c6837eb4b65f6ee42aaac2c52bb48 | |
| Appare nelle tipologie: | 1.01 Articolo in rivista |
File in questo prodotto:
| File | Descrizione | Tipologia | Licenza | |
|---|---|---|---|---|
| 1-s2.0-S1878875019328190-main.pdf | Versione Editoriale | Administrator Richiedi una copia |
Copyright © 2021